Martin Holst Lange, Novo Nordisk’s executive vice president for development, said Novo was “encouraged” by the data. He said only 57% of patients in the trial reached the highest dose.

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

CagriSema, a drug that Novo had hoped would become the next generation weight-loss aid, failed to meet expectations in ...

This was achieved even though only 57% of patients reached the highest CagriSema dose,” said Martin Holst Lange, executive vice president for development at Novo Nordisk, in a statement Friday.

Bad news for Novo Nordisk (NVO-1.99% ... 1 trial," said Novo's Executive Vice President for Development Martin Lange, noting that the company plans to "further explore the additional weight ...

Despite falling short of previously announced targets Novo Nordisk is still positive on meeting the primary endpoint of ...

Novo Nordisk shares have plunged 20% amid the disappointing trial result of its latest weight-loss drug CagriSema. The fall ...

we plan to further explore the additional weight loss potential of CagriSema," said Martin Holst Lange, executive vice president for Development at Novo Nordisk. The company stated: "The results ...

Martin Holst Lange, Novo Nordisk's executive vice president for development, said Novo was "encouraged" by the data. The company said that at the end of the 68-week trial, 57% of patients were on ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli ... in monotherapy,” Martin Holst Lange, executive vice president for ...

Novo Nordisk had targeted an average of 25 per cent weight loss from its new drug. Martin Holst Lange, the company’s executive vice-president for development, said that only 57 per cent of ...